How to Get Wegovy Covered by Insurance (and What to Do If It Says No)

Getting insurance to pay for Wegovy or Zepbound comes down to three things: confirming the exact product is on your plan’s formulary, meeting the plan’s prior-authorization criteria on the first submission, and using the appeal and external-review process if the plan says no. Your prescriber’s decision matters, but the plan’s written rules decide the outcome — and in 2026, 7% of commercially insured people, nearly 13 million, have no coverage for any GLP-1 or GIP agonist prescribed for weight loss ^[7]. Among those who do have coverage, 88% face added requirements such as prior authorization or step therapy ^[7].

If the answer is no, the path is a denial letter, up to two internal appeals, and then external review — an independent decision the insurer is required by law to accept, requested in writing within 4 months of the final denial ^[5][6]. This page covers each step, using published payer policies as examples of what plans actually ask for. It is coverage and administrative information, not medical advice; decisions about medications belong with you and your provider.

Why does coverage vary so much between plans?

Each employer or insurer decides which drugs its formulary covers and under what rules. The result in 2026, according to GoodRx tracking of commercial and exchange covered lives (last updated July 10, 2026), looks like this ^[7]:

Drug (weight-loss use)	No coverage	Restricted coverage	Unrestricted coverage
Zepbound (tirzepatide)	59.5%	36.8%	3.7%
Wegovy (semaglutide)	14.2%	76.7%	9.1%
Foundayo (orforglipron)	34.5%	57.5%	8.0%

More than 114 million people have no coverage for Zepbound, up from 51% no-coverage in 2025, while 27 million still lack coverage for Wegovy ^[7]. An uncovered weight-loss fill can exceed $1,400 per month, even for people who have insurance ^[7].

Coverage also changes mid-year. Cigna stopped covering Zepbound and Wegovy for its own employees in June 2026, while CVS Caremark is adding Zepbound back to its standard formulary in October 2026 after removing it the year before ^[7]. Checking your plan’s current documents — not last year’s — matters.

Does it matter which product or dosage form is requested?

Yes. Plans price and rule on each product and form separately, so the specific item on the prescription determines which criteria apply.

Wegovy injection carries FDA indications for reducing the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and either obesity or overweight; for weight reduction in adults and pediatric patients aged 12 and older with obesity, or adults with overweight plus at least one weight-related comorbidity; and for noncirrhotic MASH with F2–F3 fibrosis in adults, under accelerated approval ^[2]. Wegovy tablets carry the MACE and adult weight-reduction indications, but not the pediatric or MASH indications ^[2]. Wegovy HD is the 7.2 mg semaglutide injection, and CVS Caremark’s criteria exclude it from the MASH, pediatric, and cardiovascular risk-reduction pathways ^[2]. Zepbound is tirzepatide, and payer criteria address weight loss and moderate-to-severe obstructive sleep apnea ^[1]. Foundayo is orforglipron, an oral GLP-1 for weight loss approved by the FDA in April 2026 ^[7].

The label also states that using Wegovy tablets or injection together with other semaglutide products or any other GLP-1 agonist is not recommended ^[2]. And UnitedHealthcare’s program notes that Foundayo and the Wegovy tablet may be “Exclude at Launch” on some plans, even when other forms are covered ^[1].

How do I check if Wegovy or Zepbound is on my formulary?

The formulary is your plan’s covered drug list. Drugs on it are assigned to tiers, and your out-of-pocket cost depends on the tier ^[4]. Start with the plan’s drug-list documents or cost tool, then confirm the specific product, because not all listed medications are covered by all plans — Express Scripts, for example, tells members to check their own benefit materials for the specific medications covered and the copays ^[3].

Formularies come in different shapes. As an example, the Blue Cross and Blue Shield Federal Employee Program (FEP) describes three: FEP Blue Focus has a limited (closed) formulary covering only some FDA-approved drugs; FEP Blue Basic has a managed formulary with a “Managed Not Covered” list; and FEP Blue Standard is comprehensive with a small excluded-drug list ^[4]. Members taking a Managed Not Covered or Excluded drug pay the full cost of the prescription ^[4]. FEP Blue Standard and Basic use five tiers (generic, preferred brand, non-preferred brand, preferred specialty, non-preferred specialty), while FEP Blue Focus uses two ^[4].

Excluded-drug lists pair each excluded medication with preferred alternatives ^[3]. If there is a clinical reason to stay on an excluded drug, the physician can request a coverage review — for Express Scripts plans, through the portal at esrx.com/PA ^[3].

Two more things to check: supply or quantity limits may apply to weight-loss drugs ^[1], and your plan’s summary plan description must include a description of all claims procedures, including any preauthorization or utilization-review procedures and the applicable time frames ^[5].

What should I ask my plan on the phone?

Call the number on your prescription ID card ^[3] and ask for specifics, not generalities:

• Is the exact product (Wegovy injection, Wegovy tablet, Wegovy HD, Zepbound) on the formulary, and at what tier?
• Is prior authorization or step therapy required, and what are the written criteria?
• Is there a pharmacy deductible separate from the medical deductible?
• What supply or quantity limits apply?
• What is the process and deadline for appeals and external review?

Your provider can request the formulary criteria directly from the plan ^[4]. Some criteria documents are public and named: UnitedHealthcare’s Clinical Pharmacy Program for weight-loss medications is document 2026 P 1114-22, effective September 1, 2026, and CVS Caremark’s Wegovy policy is 4774-C ^[1][2]. Asking for the policy number and effective date helps ensure the submission matches the current rules.

As examples of submission routes, FEP prior approval can be submitted by a provider electronically, by fax, or by mail ^[4]. FEP formulary exception lines are 1-877-727-3784 for Traditional FEHB/PSHB and 1-855-344-0930 for the Medicare Prescription Drug Program; retail customer care is 1-800-624-5060, mail service 1-800-262-7890, and specialty 1-888-346-3731 ^[4].

You can also appoint an authorized representative — a family member, advocate, or clinician — to act on a claim or appeal, and the plan cannot preclude this ^[5][6].

What does prior authorization actually require?

Published payer policies show what a complete first submission looks like. These are examples from two large payers, not rules that apply to every plan — your plan’s own criteria control.

UnitedHealthcare’s program (effective September 1, 2026) approves initial requests when all of the following are met: a qualifying reason for treatment; an age rule (12 or older for Wegovy injection, over 16 for most other products including Zepbound, with pediatric BMI at or above the 95th percentile); use as an adjunct to lifestyle modification such as dietary or caloric restriction, exercise, behavioral support, or a community-based program; and a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher plus a weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes, or sleep apnea ^[1].

CVS Caremark’s Wegovy policy 4774-C requires for adults 18 and older: participation in a comprehensive weight management program — behavior modification, reduced-calorie diet, and increased physical activity — with continuing follow-up for at least 6 months before drug therapy, plus a baseline BMI of 30 or higher, or 27 or higher with at least one comorbidity, all documented ^[2]. Its pediatric pathway covers Wegovy injection only, for ages 12–17, with a baseline BMI at or above the 95th percentile for age and sex plus the same 6-month program requirement ^[2].

Initial approvals run for a fixed period ^[1]:

Product	Initial authorization length (UHC)
Wegovy injection or tablet, Wegovy HD	5 months
Zepbound, Foundayo, Xenical	6 months
Contrave, Qsymia, Saxenda	4 months
Phentermine, benzphetamine, diethylpropion, phendimetrazine	3 months

For reauthorization, UnitedHealthcare requires weight loss of at least 5% of baseline body weight for Wegovy injection or tablet, Wegovy HD, Zepbound, and most other agents (3% for Qsymia, 4% for Saxenda), plus continued lifestyle modification; renewed authorizations run 12 months ^[1]. CVS Caremark’s continuation requires at least 3 months at a stable maintenance dose and documented loss or maintenance of at least 5% of baseline body weight ^[2].

The chart items plans ask to see are consistent across both policies: a documented baseline BMI, any weight-related comorbidity, participation in a lifestyle or weight-management program, and — if switching from another drug — the baseline values at the start of the earlier therapy ^[1][2].

State rules can change the numbers. UnitedHealthcare’s criteria for North Dakota fully insured essential-health-benefit plans require a BMI of 40 kg/m² or higher, or a pediatric BMI at or above 120% of the 95th percentile, and the program is built to meet mandates in California, New Mexico, North Dakota EHB, and New York ^[1].

What if my plan covers the drug only for another condition?

Some plans that exclude weight-loss coverage still cover the molecule for other FDA indications. UnitedHealthcare maintains separate “Nonformulary Wegovy” and “Nonformulary Zepbound” criteria specifically for plans that do not cover weight-loss medications ^[1]. Within the same policies, separate indication pathways exist: Wegovy for MACE risk reduction, Wegovy injection for MASH with F2–F3 fibrosis, and Zepbound for moderate-to-severe obstructive sleep apnea ^[1][2].

The CVS Caremark cardiovascular pathway has its own requirements: documented prior MI, stroke, symptomatic peripheral arterial disease (ABI below 0.85, revascularization, or amputation), or prior revascularization; a BMI of 27 or higher; no type 2 diabetes; and current guideline-directed medical therapy or a documented reason not to be on it ^[2]. Its MASH pathway requires F2–F3 fibrosis confirmed by elastography, MRE, or historical biopsy, and prescribing by or in consultation with a gastroenterologist or hepatologist; it excludes Wegovy HD and tablets ^[2]. Note that under Caremark criteria, Ozempic — not Wegovy — is the pathway for cardiovascular risk reduction in patients with type 2 diabetes ^[2].

Which pathway applies depends on the documented diagnosis in the medical record, not on which one is easier to satisfy.

What if the drug is excluded from my formulary?

An exclusion is not always the end. Under BCBS FEP, an excluded or non-covered weight-loss GLP-1 can still be obtained if the provider submits a formulary exception request that meets the exception guidelines ^[4].

But a formulary exception has limits. It does not change out-of-pocket costs ^[4]. After an approved exception in 2026, FEP Blue Focus places Wegovy and Zepbound in Tier 2 (preferred), while FEP Blue Basic and Standard place Zepbound in Tier 3 (non-preferred) — and even when the GLP-1 is approved, a tier exception cannot be requested ^[4]. Approved exceptions last only to their stated expiration date, after which a new exception must be requested ^[4]. FEP uses a Traditional Formulary Exception Form and a separate MPDP Formulary Exception Form ^[4].

On Express Scripts plans, the route for an excluded drug is a prescriber-initiated coverage review when there is a clinical reason to continue it, via esrx.com/PA ^[3].

What happens after a denial: the internal appeal ladder

Read the denial letter first. FEP, for example, mails the denial letter to both the member and the provider, and it explains appeal rights and next steps ^[4].

Federal claims rules under ERISA set the guardrails. A plan cannot require more than two internal appeals of an adverse benefit determination before a civil action under ERISA section 502(a) ^[5]. If a plan offers voluntary extra appeal levels, they must be free, the plan cannot argue you failed to exhaust remedies by skipping them, and the statute of limitations is tolled while they are pending ^[5]. Plans may not charge a fee as a condition of filing a claim or appeal ^[5], and claims procedures must apply plan provisions consistently among similarly situated claimants ^[5]. If a pre-service claim is filed improperly, the plan must notify the claimant of the correct procedure within 5 days — 24 hours for urgent care ^[5].

How does external review work?

If internal appeals are exhausted, external review puts the decision in the hands of an independent reviewer. The request must be in writing within 4 months after receiving the notice of final denial ^[6]. A standard external review is decided no later than 45 days after the request is received; an expedited review is decided no later than 72 hours ^[6]. The insurer is required by law to accept the external reviewer’s decision ^[6].

Denials eligible for external review include those involving medical judgment, determinations that a treatment is experimental or investigational, and rescission of coverage ^[6]. Cost: free under the HHS-administered federal process, and otherwise no more than $25 per external review ^[6].

Where your state’s external review process meets or exceeds federal standards, the state process applies; otherwise HHS oversees the process ^[6]. For the HHS-administered process, requests can be made by phone at 1-888-866-6205 for a request form, by fax at 1-888-866-6190, by email at ferp@maximus.com, or by mail to MAXIMUS Federal Services, 3750 Monroe Avenue, Suite 705, Pittsford, NY 14534 ^[6]. A deadline extension to October 2, 2026 applies to HHS-administered requests originally due between July 1 and August 3, 2026, affecting Alabama, Florida, Georgia, Texas, Wisconsin, some territories, and state and local government plans ^[6].

A doctor or another representative who knows your condition can file the external review for you, and help is available from your state’s Consumer Assistance Program or Department of Insurance ^[6].

What if it’s approved but still expensive?

Approval is not the same as affordable. The tier determines out-of-pocket cost, and FEP moved weight-loss GLP-1s between tiers citing the rapid increase in their use as the main factor driving costs ^[4]. Coverage status also does not account for deductibles: some plans have a separate pharmacy-only deductible, which means paying full price for medications until it is met ^[7].

Pharmacy network rules matter too. FEP Blue Standard members who use a non-preferred pharmacy pay the full amount up front and file a claim for reimbursement, while FEP Blue Basic and Focus members cannot use the pharmacy benefit at non-preferred pharmacies at all ^[4]. The CVS Caremark FEP network includes more than 55,000 preferred pharmacies ^[4]. The FEP Medicare Prescription Drug Program has four tiers and an annual out-of-pocket cap; the traditional pharmacy benefit does not ^[4].

What should I compare at open enrollment?

If you can change plans, compare each option on five points: whether the exact product is listed, its tier, prior-authorization or step-therapy requirements, the deductible (including any pharmacy-only deductible), and the out-of-pocket maximum ^[4][7].

Be realistic about the odds. A review of 2026 ACA Marketplace carriers found that only 26 of 300 cover GLP-1s for obesity treatment, and only nine states have any Marketplace plans offering such coverage ^[8]. Marketplace enrollees with GLP-1 obesity coverage fell from 3.6 million in 2024 to 2.8 million in 2026, and the conditions of access are more restrictive than the prior year ^[8]. That review covered Wegovy, Zepbound, and Saxenda policies under the Obesity Coverage Nexus / LEVERAGE project, funded by the Robert Wood Johnson Foundation ^[8].

State mandates can also change criteria from year to year — UnitedHealthcare notes mandate-driven variants for California, New Mexico, North Dakota EHB, and New York — so the same carrier’s rules can differ by state ^[1].

Sources

1. UnitedHealthcare Pharmacy. Prior Authorization/Notification - Plans with Weight Loss/Appetite Suppression Medication Coverage. Program Number 2026 P 1114-22.
2. CVS Caremark. Initial Prior Authorization with Quantity Limit - Wegovy Weight Loss Management.
3. Express Scripts. 2026 Express Scripts National Preferred Formulary Exclusions.
4. Blue Cross and Blue Shield Federal Employee Program. FAQ - Pharmacy.
5. Legal Information Institute, Cornell Law School. 29 CFR § 2560.503-1 - Claims procedure.
6. HealthCare.gov. Appealing a health plan decision: External Review.
7. GoodRx. Live Updates: Insurance Coverage for GIP and GLP-1 Agonists Like Zepbound & Wegovy in 2026.
8. AXIACI. Marketplace Plans: GLP-1s in 2026 - Coverage Shrinks as Barriers to Access Expand.
9. KFF. 2025 Employer Health Benefits Survey. October 22, 2025.
10. Medicaid and CHIP Payment and Access Commission. Prior Authorization in Medicaid. August 2024.
11. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: Information for Providers.
12. PR Newswire. FDA approves Novo Nordisk’s new Wegovy HD injection, delivering the highest weight loss to date for a Wegovy injection. March 19, 2026.
13. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.